Exploring the Potential of Pemafibrate in Reducing Diabetic Foot Ulceration and Gangrene
Note: This post was also part of a Med Page Today interview here
Diabetic foot ulceration remains a significant challenge in the management of type 2 diabetes, often leading to increased risks of amputation and mortality. This condition affects up to 34% of individuals with diabetes in their lifetime, predominantly due to the complications arising from peripheral artery disease (PAD). The recent study published in the Journal of the American College of Cardiology by Marinho et al. provides promising insights into the potential of pemafibrate, a selective peroxisome proliferator-activated receptor alpha (PPAR-a) modulator, in addressing this critical issue.
The Clinical Question
The primary question addressed by the study was whether pemafibrate, compared to a placebo, could reduce the incidence of diabetic lower extremity ulceration and gangrene. This question is particularly relevant given the lack of effective medical therapies for ischemic lower extremity ulceration in diabetic patients.
Main Findings
In an exploratory analysis of the large-scale PROMINENT trial, the authors found that pemafibrate reduced the incidence of diabetic lower extremity ulceration and gangrene by 37% (HR: 0.63; 95% CI: 0.41-0.96; P = 0.03). This finding is significant as it suggests that pemafibrate could provide a much-needed therapeutic option for patients with diabetes who are at high risk of developing these severe complications.
Study Details
The PROMINENT trial was a multinational, double-blind, randomized, placebo-controlled study involving 10,497 participants with type 2 diabetes, mild to moderate hypertriglyceridemia, and low high-density lipoprotein cholesterol levels. The participants were administered pemafibrate (0.2 mg orally twice daily) and were followed for a median of 3.4 years. The study’s Clinical Endpoints Committee adjudicated all reports of incident PAD, including ischemic ulceration and gangrene, in a blinded manner.
During the follow-up period, 35 incident events of lower extremity ulceration or gangrene occurred in the pemafibrate group compared to 56 in the placebo group. This translated to incidence rates of 2.1 per 1,000 person-years in the pemafibrate group and 3.4 per 1,000 person-years in the placebo group.
Implications and Future Directions
The results of this study are consistent with previous evidence showing the benefits of PPAR-a agonists in other diabetic microvascular complications, such as minor amputations and diabetic retinopathy. These findings underscore the potential of pemafibrate as a therapeutic approach for reducing the risk of lower extremity ischemic ulceration and gangrene.
Given these promising results, further prospective investigations are warranted. Two upcoming placebo-controlled trials are anticipated to explore whether pemafibrate can accelerate the healing of existing diabetic foot ulcerations and prevent recurrent ulceration among individuals with recently healed ulcers.
Limitations
The study’s exploratory nature and the modest number of total events are notable limitations. Additionally, the generalizability of the findings may be limited as the PROMINENT trial only included patients with diabetes who had moderate hypertriglyceridemia and well-controlled cholesterol levels.
Conclusion
The exploratory analysis by Marinho et al. provides compelling evidence that pemafibrate may offer a new therapeutic avenue for reducing the incidence of diabetic foot ulceration and gangrene. These findings hold significant promise for improving the management and outcomes of patients with diabetes at high risk for these severe complications.
For more detailed information, please refer to the original study: Marinho LL, Everett BM, Aday AW, et al. Effect of Pemafibrate on Diabetic Foot Ulceration and Gangrene: An Exploratory Analysis From PROMINENT. J Am Coll Cardiol. 2024;84(4):408-410. doi:10.1016/j.jacc.2024.05.028.
Leave a Reply